Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel
NASDAQ:CRVS

Corvus Pharmaceuticals Q3 2026 Earnings Date & Estimates

Corvus Pharmaceuticals logo
$10.03 -0.20 (-1.96%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$10.02 0.00 (-0.05%)
As of 10/30/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corvus Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Corvus Pharmaceuticals in Q3 2026

Corvus Pharmaceuticals is expected to post earnings of -$0.1921 per share. In the same quarter a year earlier Corvus Pharmaceuticals reported -$0.12 per share. Corvus Pharmaceuticals last reported on August 6, 2026, posting -$0.19 per share and missing the -$0.1591 consensus estimate. Corvus Pharmaceuticals has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.1921
Prior-Year EPS
-$0.12

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.19 (Missed by -$0.0309)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Corvus Pharmaceuticals Q3 2026 Earnings FAQ

Corvus Pharmaceuticals (NASDAQ:CRVS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Corvus Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Corvus Pharmaceuticals to post earnings of -$0.1921 per share for Q3 2026.

Corvus Pharmaceuticals Earnings Headlines

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
October 29 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391204/0/en/corvus-pharmaceuticals-to-provide-business-update-and-third-quarter-2026-financial-results-on-november-5-2026.html
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock Has Consensus Price Target of $33.33 According to Brokerages
October 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148289
What Elon Musk's Cybercab Reveal Could Mean for Investors
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.tc pixel
 |  Brownstone Research (Ad)
Corvus Advances Soquelitinib Trial in Hidradenitis Suppurativa: What Investors Should Watch
October 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/corvus-advances-soquelitinib-trial-in-hidradenitis-suppurativa-what-investors-should-watch?utm_source=marketbeat.com&utm_medium=referral
Corvus Begins Patient Enrollment In Phase 1b Soquelitinib Trial For Hidradenitis Suppurativa
October 1, 2026  |  rttnews.comhttps://www.rttnews.com/3695601/corvus-begins-patient-enrollment-in-phase-1b-soquelitinib-trial-for-hidradenitis-suppurativa.aspx
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
September 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3372383/0/en/corvus-pharmaceuticals-announces-initiation-of-phase-1b-clinical-trial-of-soquelitinib-for-patients-with-hidradenitis-suppurativa.html
See More Corvus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corvus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corvus Pharmaceuticals and other key companies, straight to your email.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on developing medicines that harness the immune system to treat cancer. The company’s research centers on therapies designed to modulate immune-cell activity and address diseases with significant unmet medical needs.

Corvus’ leading product candidate is soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of inducible T-cell kinase (ITK). The company is studying soquelitinib as a potential treatment for T-cell malignancies, including peripheral T-cell lymphoma. Corvus has also investigated mupadolimab, formerly CPI-006, an antibody targeting CD73, an immunosuppressive protein associated with cancer and immune regulation.

Corvus Pharmaceuticals was founded in 2014 and is headquartered in Burlingame, California. Its therapies have been evaluated through clinical-development programs involving patients in the United States and other regions, although the company’s primary activities remain research, clinical testing and development rather than commercial product sales. Richard A. Miller, M.D., a co-founder, serves as president and chief executive officer.

View Corvus Pharmaceuticals Profile
Earnings Tools